Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 1/2023

01.06.2022

Autoimmunity in Primary Immunodeficiencies (PID)

verfasst von: Grace T. Padron, Vivian P. Hernandez-Trujillo

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Primary immunodeficiency (PID) may impact any component of the immune system. The number of PID and immune dysregulation disorders is growing steadily with advancing genetic detection methods. These expansive recognition methods have changed the way we characterize PID. While PID were once characterized by their susceptibility to infection, the increase in genetic analysis has elucidated the intertwined relationship between PID and non-infectious manifestations including autoimmunity. The defects permitting opportunistic infections to take hold may also lead the way to the development of autoimmune disease. In some cases, it is the non-infectious complications that may be the presenting sign of PID autoimmune diseases, such as autoimmune cytopenia, enteropathy, endocrinopathies, and arthritis among others, have been reported in PID. While autoimmunity may occur with any PID, this review will look at certain immunodeficiencies most often associated with autoimmunity, as well as their diagnosis and management strategies.
Literatur
1.
Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N (2017) Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol 140(5):1388-1393.e1388PubMedCrossRef
2.
3.
Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS et al (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123(13):1989–1999PubMedPubMedCentralCrossRef
4.
Hadjadj J, Aladjidi N, Fernandes H, Leverger G, Magérus-Chatinet A, Mazerolles F, Stolzenberg MC, Jacques S, Picard C, Rosain J et al (2019) Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 134(1):9–21PubMedCrossRef
5.
Seidel MG (2014) Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 124(15):2337–2344PubMedPubMedCentralCrossRef
6.
Gambineri E, Ciullini Mannurita S, Hagin D, Vignoli M, Anover-Sombke S, DeBoer S, Segundo GRS, Allenspach EJ, Favre C, Ochs HD et al (2018) Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Front Immunol 9:2411PubMedPubMedCentralCrossRef
7.
Kisand K, Peterson P (2015) Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 35(5):463–478PubMedCrossRef
8.
Cunningham-Rundles C, Maglione PJ (2012) Common variable immunodeficiency. J Allergy Clin Immunol 129(5):1425-1426.e1423PubMedCrossRef
9.
Buchbinder D, Nugent DJ, Fillipovich AH (2014) Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet 7:55–66PubMedPubMedCentralCrossRef
10.
Falcone EL, Holland SM (2019) Gastrointestinal complications in chronic granulomatous disease. Methods Mol Biol 1982:573–586PubMedCrossRef
11.
Chan AY, Leiding JW, Liu X, Logan BR, Burroughs LM, Allenspach EJ, Skoda-Smith S, Uzel G, Notarangelo LD, Slatter M et al (2020) Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): a Primary Immune Deficiency Treatment Consortium (PIDTC) survey. Front Immunol 11:239PubMedPubMedCentralCrossRef
12.
Saifi M, Wysocki CA (2015) Autoimmune disease in primary immunodeficiency: at the crossroads of anti-infective immunity and self-tolerance. Immunol Allergy Clin 35(4):731–752
13.
Grimbacher B, Warnatz K, Yong PF, Korganow A-S, Peter H-H (2016) The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects. J Allergy Clin Immunol 137(1):3–17PubMedCrossRef
14.
Giardino G, Gallo V, Prencipe R, Gaudino G, Romano R, De Cataldis M, Lorello P, Palamaro L, Di Giacomo C, Capalbo D (2016) Unbalanced immune system: immunodeficiencies and autoimmunity. Front Pediatr 4:107PubMedPubMedCentralCrossRef
15.
Schröder-Braunstein J, Kirschfink M (2019) Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 114:299–311PubMedCrossRef
16.
Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, Hussey AA, Evbuomwan MO, Priel DAL, Kuhns DB (2013) Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood TJ Am Soc Hematol 121(16):3117–3125
17.
Costagliola G, Cappelli S, Consolini R (2021) Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications. J Clin Med 10(20):4729PubMedPubMedCentralCrossRef
18.
Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM et al (2020) Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol 40(1):66–81PubMedPubMedCentralCrossRef
19.
Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O’Reilly RJ, Fleisher TA et al (2014) Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 133(4):1092–1098PubMedCrossRef
20.
21.
22.
de Saint-Basile G, Le Deist F, de Villartay JP, Cerf-Bensussan N, Journet O, Brousse N, Griscelli C, Fischer A (1991) Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn’s syndrome). J Clin Invest 87(4):1352–1359PubMedPubMedCentralCrossRef
23.
Bai X, Liu J, Zhang Z, Liu C, Zhang Y, Tang W, Dai R, Wu J, Tang X, Zhang Y et al (2016) Clinical, immunologic, and genetic characteristics of RAG mutations in 15 Chinese patients with SCID and Omenn syndrome. Immunol Res 64(2):497–507PubMedCrossRef
24.
Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR, Schwarz K, Pannicke U (2005) Omenn syndrome due to ARTEMIS mutations. Blood 105(11):4179–4186PubMedCrossRef
25.
Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, Friedrich W, Seger RA, Hansen-Hagge TE, Desiderio S et al (1996) RAG mutations in human B cell-negative SCID. Science 274(5284):97–99PubMedCrossRef
26.
Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, Gatta LB, Ochs HD, Schwarz K, Notarangelo LD et al (1998) Partial V(D)J recombination activity leads to Omenn syndrome. Cell 93(5):885–896PubMedCrossRef
27.
Rieux-Laucat F, Bahadoran P, Brousse N, Selz F, Fischer A, Le Deist F, De Villartay JP (1998) Highly restricted human T cell repertoire in peripheral blood and tissue-infiltrating lymphocytes in Omenn’s syndrome. J Clin Invest 102(2):312–321PubMedPubMedCentralCrossRef
28.
Signorini S, Imberti L, Pirovano S, Villa A, Facchetti F, Ungari M, Bozzi F, Albertini A, Ugazio AG, Vezzoni P et al (1999) Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood 94(10):3468–3478PubMedCrossRef
29.
Le Deist F, Fischer A, Durandy A, Arnaud-Battandier F, Nezelof C, Hamet M, de Prost Y, Griscelli C (1985) Severe combined immune deficiency with hypereosinophilia: Immunologic study of 5 cases. Arch Fr Pediatr 42(1):11–16PubMed
30.
Facchetti F, Blanzuoli L, Ungari M, Alebardi O, Vermi W (1998) Lymph node pathology in primary combined immunodeficiency diseases. Springer Semin Immunopathol 19(4):459–478PubMedCrossRef
31.
Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, Sediva A, Marrella V, Villa A, Fischer A et al (2005) AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 115(3):728–732PubMedPubMedCentralCrossRef
32.
Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, Vairo D, Plebani A, Giliani S, Vezzoni P et al (2010) Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol 125(1):209–216PubMedCrossRef
33.
Kaino Y, Otoh Y, Tokuda K, Hirai H, Ito T, Kida K (2000) Acquired hypothyroidism in a very young infant with Omenn’s syndrome. J Pediatr 136(1):111–113PubMedCrossRef
34.
Rigoni R, Fontana E, Guglielmetti S, Fosso B, D’Erchia AM, Maina V, Taverniti V, Castiello MC, Mantero S, Pacchiana G et al (2016) Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects. J Exp Med 213(3):355–375PubMedPubMedCentralCrossRef
35.
Zago CA, Jacob CM, de Albuquerque Diniz EM, Lovisolo SM, Zerbini MC, Dorna M, Watanabe L, Fernandes JF, Rocha V, Oliveira JB et al (2014) Autoimmune manifestations in SCID due to IL7R mutations: Omenn syndrome and cytopenias. Hum Immunol 75(7):662–666PubMedCrossRef
36.
Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, Chen A, Kim HS, Lloret MG, Schulze I et al (2009) Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 124(6):1289-1302.e1284PubMedPubMedCentralCrossRef
37.
Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, Matthews HF, Davis J, Turner ML, Uzel G et al (2009) Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 361(21):2046–2055PubMedPubMedCentralCrossRef
38.
Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, Kostyuchenko L, Genel F, Kütükcüler N, Karaca N et al (2015) DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol 35(2):189–198PubMedCrossRef
39.
Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, Saghafi S, Pourpak Z, Ceja R, Sassi A et al (2015) The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 136(2):402–412PubMedPubMedCentralCrossRef
40.
41.
Jouhadi Z, Khadir K, Ailal F, Bouayad K, Nadifi S, Engelhardt KR, Grimbacher B (2014) Ten-year follow-up of a DOCK8-deficient child with features of systemic lupus erythematosus. Pediatrics 134(5):e1458-1463PubMedCrossRef
42.
Etzioni A, Ochs HD (2004) The hyper IgM syndrome–an evolving story. Pediatr Res 56(4):519–525PubMedCrossRef
43.
Qamar N, Fuleihan RL (2014) The hyper IgM syndromes. Clin Rev Allergy Immunol 46(2):120–130PubMedCrossRef
44.
Lougaris V, Badolato R, Ferrari S, Plebani A (2005) Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 203:48–66PubMedCrossRef
45.
Jesus AA, Duarte AJ, Oliveira JB (2008) Autoimmunity in hyper-IgM syndrome. J Clin Immunol 28(Suppl 1):S62-66PubMedCrossRef
46.
Lougaris V, Lanzi G, Baronio M, Gazzurelli L, Vairo D, Lorenzini T, Badolato R, Notarangelo LD, Boschi A, Moratto D et al (2018) Progressive severe B cell and NK cell deficiency with T cell senescence in adult CD40L deficiency. Clin Immunol 190:11–14PubMedCrossRef
47.
Wolpert KA, Webster AD, Whittaker SJ (1998) Discoid lupus erythematosus associated with a primary immunodeficiency syndrome showing features of non-X-linked hyper-IgM syndrome. Br J Dermatol 138(6):1053–1057PubMedCrossRef
48.
49.
Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, Geha RS, Cunningham CK, Bonilla FA, Conley ME et al (2016) Hyper IgM syndrome: a report from the USIDNET Registry. J Clin Immunol 36(5):490–501PubMedPubMedCentralCrossRef
50.
Azzu V, Kennard L, Morillo-Gutierrez B, Slatter M, Edgar JDM, Kumararatne DS, Griffiths WJH (2018) Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper-IgM but can be prevented by early hematopoietic stem cell transplantation. J Allergy Clin Immunol 141(1):405-408.e407PubMedCrossRef
51.
Woellner C, Gertz EM, Schäffer AA, Lagos M, Perro M, Glocker EO, Pietrogrande MC, Cossu F, Franco JL, Matamoros N et al (2010) Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 125(2):424-432.e428PubMedPubMedCentralCrossRef
52.
Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O et al (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448(7157):1058–1062PubMedCrossRef
53.
Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML et al (2007) STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357(16):1608–1619PubMedCrossRef
54.
55.
56.
North J, Kotecha S, Houtman P, Whaley K (1997) Systemic lupus erythematosus complicating hyper IgE syndrome. Br J Rheumatol 36(2):297–298PubMedCrossRef
57.
Brugnoni D, Franceschini F, Airò P, Cattaneo R (1998) Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins. Br J Rheumatol 37(7):807–808PubMedCrossRef
58.
Yamazaki-Nakashimada M, Zaltzman-Girshevich S, Garcia de la Puente S, De Leon-Bojorge B, Espinosa-Padilla S, Saez-de-Ocariz M, Carrasco-Daza D, Hernandez-Bautista V, Pérez-Fernandez L, Espinosa-Rosales F (2006) Hyper-IgE syndrome and autoimmunity in Mexican children. Pediatr Nephrol 21(8):1200–1205PubMedCrossRef
59.
Saikia B, Aneja H, Jain J, Puliyel JM (2013) Hyperimmunoglobulin E syndrome with juvenile dermatomyositis and calcinosis. Clin Rheumatol 32(Suppl 1):S51-53PubMedCrossRef
60.
Erbagci Z (2008) Childhood bullous pemphigoid in association with hyperimmunoglobulin E syndrome. Pediatr Dermatol 25(1):28–33PubMedCrossRef
61.
Albert MH, Notarangelo LD, Ochs HD (2011) Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol 18(1):42–48PubMedCrossRef
62.
Derry JM, Ochs HD, Francke U (1994) Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78(4):635–644PubMedCrossRef
63.
Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, Bleesing JJ, Edwards S, Dvorak CC, Chaudhury S et al (2020) Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood 135(23):2094–2105PubMedPubMedCentralCrossRef
64.
Ferrua F, Marangoni F, Aiuti A, Roncarolo MG (2020) Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions. J Allergy Clin Immunol 146(2):262–265PubMedPubMedCentralCrossRef
65.
66.
Kirkpatrick JA Jr, DiGeorge AM (1968) Congenital absence of the thymus. Am J Roentgenol Radium Ther Nucl Med 103(1):32–37PubMedCrossRef
67.
Conley ME, Beckwith JB, Mancer JF, Tenckhoff L (1979) The spectrum of the DiGeorge syndrome. J Pediatr 94(6):883–890PubMedCrossRef
68.
Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, Kobrynski LJ, Komarow HD, Mazer B et al (2015) Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 136(5):1186–1205PubMedCrossRef
69.
Farley AM, Morris LX, Vroegindeweij E, Depreter ML, Vaidya H, Stenhouse FH, Tomlinson SR, Anderson RA, Cupedo T, Cornelissen JJ et al (2013) Dynamics of thymus organogenesis and colonization in early human development. Development 140(9):2015–2026PubMedPubMedCentralCrossRef
70.
Gardiner JR, Jackson AL, Gordon J, Lickert H, Manley NR, Basson MA (2012) Localised inhibition of FGF signalling in the third pharyngeal pouch is required for normal thymus and parathyroid organogenesis. Development 139(18):3456–3466PubMedPubMedCentralCrossRef
71.
Thomas RA, Landing BH, Wells TR (1987) Embryologic and other developmental considerations of thirty-eight possible variants of the DiGeorge anomaly. Am J Med Genet Suppl 3:43–66PubMedCrossRef
72.
73.
de Lonlay-Debeney P, Cormier-Daire V, Amiel J, Abadie V, Odent S, Paupe A, Couderc S, Tellier AL, Bonnet D, Prieur M et al (1997) Features of DiGeorge syndrome and CHARGE association in five patients. J Med Genet 34(12):986–989PubMedPubMedCentralCrossRef
74.
Rope AF, Cragun DL, Saal HM, Hopkin RJ (2009) DiGeorge anomaly in the absence of chromosome 22q11.2 deletion. J Pediatr 155(4):560–565PubMedCrossRef
75.
76.
Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sempowski GD, Rhein ME, Szabolcs P, Hale LP et al (2004) Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 113(4):734–741PubMedCrossRef
77.
Wang HX, Pan W, Zheng L, Zhong XP, Tan L, Liang Z, He J, Feng P, Zhao Y, Qiu YR (2019) Thymic epithelial cells contribute to thymopoiesis and T cell development. Front Immunol 10:3099PubMedCrossRef
78.
79.
Giardino G, Radwan N, Koletsi P, Morrogh DM, Adams S, Ip W, Worth A, Jones A, Meyer-Parsonson I, Gaspar HB et al (2019) Clinical and immunological features in a cohort of patients with partial DiGeorge syndrome followed at a single center. Blood 133(24):2586–2596PubMedCrossRef
80.
Tison BE, Nicholas SK, Abramson SL, Hanson IC, Paul ME, Seeborg FO, Shearer WT, Perez MD, Noroski LM, Chinen J (2011) Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol 128(5):1115–1117PubMedCrossRef
81.
Choi JH, Shin YL, Kim GH, Seo EJ, Kim Y, Park IS, Yoo HW (2005) Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome. Horm Res 63(6):294–299PubMed
82.
Lima K, Abrahamsen TG, Wolff AB, Husebye E, Alimohammadi M, Kämpe O, Følling I (2011) Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. Eur J Endocrinol 165(2):345–352PubMedCrossRef
83.
Lawrence S, McDonald-McGinn DM, Zackai E, Sullivan KE (2003) Thrombocytopenia in patients with chromosome 22q11.2 deletion syndrome. J Pediatr 143(2):277–278PubMedCrossRef
84.
85.
Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, Shurtleff SA (2005) Genetic analysis of patients with defects in early B-cell development. Immunol Rev 203:216–234PubMedCrossRef
86.
Conley ME, Rohrer J, Minegishi Y (2000) X-linked agammaglobulinemia. Clin Rev Allergy Immunol 19(2):183–204PubMedCrossRef
87.
Ochs HD, Smith CI (1996) X-linked agammaglobulinemia: A clinical and molecular analysis. Medicine (Baltimore) 75(6):287–299PubMedCrossRef
88.
Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, Cazzola G, Consolini R, De Mattia D, Dell’Erba G et al (2002) Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 104(3):221–230PubMedCrossRef
89.
Takada H, Kanegane H, Nomura A, Yamamoto K, Ihara K, Takahashi Y, Tsukada S, Miyawaki T, Hara T (2004) Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation. Blood 103(1):185–187PubMedCrossRef
90.
Vetrie D, Vořechovský I, Sideras P, Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky R, Bobrow M et al (1993) (2012) The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. J Immunol 188(7):2948–2955
91.
Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S et al (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72(2):279–290PubMedCrossRef
92.
Väliaho J, Smith CI, Vihinen M (2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27(12):1209–1217PubMedCrossRef
93.
Parolini O, Hejtmancik JF, Allen RC, Belmont JW, Lassiter GL, Henry MJ, Barker DF, Conley ME (1993) Linkage analysis and physical mapping near the gene for X-linked agammaglobulinemia at Xq22. Genomics 15(2):342–349PubMedCrossRef
94.
Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BMJ (2006) Bruton’s tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 176(6):3635–3641PubMedCrossRef
95.
Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, Kaneko H, Kondo N, Kaisho T, Miyawaki T (2008) Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol 126(2):148–154PubMedCrossRef
96.
Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, Walch E, Wirth T, O’Neill LA (2003) Bruton’s tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 278(28):26258–26264PubMedCrossRef
97.
Sochorová KR, Horváth R, Rožková D, Litzman J, Bartůňková J, Šedivá A, Špíšek R (2006) Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 109(6):2553–2556PubMedCrossRef
98.
Lougaris V, Baronio M, Vitali M, Tampella G, Cattalini M, Tassone L, Soresina A, Badolato R, Plebani A (2014) Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J Allergy Clin Immunol 133(6):1644-1650.e1644PubMedCrossRef
99.
100.
Farrar JE, Rohrer J, Conley ME (1996) Neutropenia in X-linked agammaglobulinemia. Clin Immunol Immunopathol 81(3):271–276PubMedCrossRef
101.
Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, Conley ME, Cunningham-Rundles C, Ochs HD (2006) X-linked agammaglobulinemia: report on a United States Registry of 201 patients. Medicine 85(4):193–202PubMedCrossRef
102.
Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, Morita R (2015) Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun 6(1):7360PubMedCrossRef
103.
Marron TU, Rohr K, Martinez-Gallo M, Yu J, Cunningham-Rundles C (2010) TLR signaling and effector functions are intact in XLA neutrophils. Clin Immunol 137(1):74–80PubMedPubMedCentralCrossRef
104.
Bonami RH, Sullivan AM, Case JB, Steinberg HE, Hoek KL, Khan WN, Kendall PL (2014) Bruton’s tyrosine kinase promotes persistence of mature anti-insulin B cells. J Immunol 192(4):1459–1470PubMedCrossRef
105.
Nyhoff LE, Barron BL, Johnson EM, Bonami RH, Maseda D, Fensterheim BA, Han W, Blackwell TS, Crofford LJ, Kendall PL (2016) Bruton’s tyrosine kinase deficiency inhibits autoimmune arthritis in mice but fails to block immune complex-mediated inflammatory arthritis. Arthritis Rheumatol 68(8):1856–1868PubMedPubMedCentralCrossRef
106.
Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, Yel L, Sullivan KE (2014) Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol 34(6):627–632PubMedPubMedCentralCrossRef
107.
Barmettler S, Otani IM, Minhas J, Abraham RS, Chang Y, Dorsey MJ, Ballas ZK, Bonilla FA, Ochs HD, Walter JE (2017) Gastrointestinal Manifestations in X-linked Agammaglobulinemia. J Clin Immunol 37(3):287–294PubMedPubMedCentralCrossRef
108.
García-García E, Staines-Boone AT, Vargas-Hernández A, González-Serrano ME, Carrillo-Tapia E, Mogica-Martínez D, Berrón-Ruíz L, Segura-Mendez NH, Espinosa-Rosales FJ, Yamazaki-Nakashimada MA et al (2016) Clinical and mutational features of X-linked agammaglobulinemia in Mexico. Clin Immunol 165:38–44PubMedCrossRef
109.
Machado P, Santos A, Faria E, Silva J, Malcata A, Chieira C (2008) Arthritis and X-linked agammaglobulinemia. Acta Reumatol Port 33(4):464–467PubMed
110.
Moisă SM, Rugină A, Moraru E, Goţia S, Burlea M (2009) X-linked Bruton congenital agammaglobulinemia: Case report. Rev Med Chir Soc Med Nat Lasi 113(1):103–107
111.
Patiroglu T, Akar HH, Gunduz Z, Sisko S, Ng YY (2015) X-linked agammaglobulinemia in two siblings with a novel mutation in the BTK gene who presented with polyarticular juvenile idiopathic arthritis. Scand J Rheumatol 44(2):168–170PubMedCrossRef
112.
Sharma D, Gupta A, Goel S, Sharma M, Rawat A, Singh S (2017) Large BTK gene mutation in a child with X-linked agammaglobulinemia and polyarthritis. Clin Immunol 183:109–111PubMedCrossRef
113.
Váncsa A, Tóth B, Szekanecz Z (2011) BTK gene mutation in two non-identical twins with X-linked agammaglobulinemia associated with polyarticular juvenile idiopathic arthritis. Isr Med Assoc J 13(9):579–580PubMed
114.
Zhu Z, Kang Y, Lin Z, Huang Y, Lv H, Li Y (2015) X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis. Clin Rheumatol 34(2):397–401PubMedCrossRef
115.
Robbins JB, Skinner RG, Pearson HA (1969) Autoimmune hemolytic anemia in a child with congenital x-linked hypogammaglobulinemia. N Engl J Med 280(2):75–79PubMedCrossRef
116.
117.
Wang N, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, Rantapää-Dahlqvist S, Elvin K, Truedsson L, Andersson BA et al (2011) Selective IgA deficiency in autoimmune diseases. Mol Med 17(11–12):1383–1396PubMedPubMedCentralCrossRef
118.
119.
Mohammadi J, Ramanujam R, Jarefors S, Rezaei N, Aghamohammadi A, Gregersen PK, Hammarström L (2010) IgA deficiency and the MHC: assessment of relative risk and microheterogeneity within the HLA A1 B8, DR3 (8.1) haplotype. J Clin Immunol 30(1):138–143PubMedCrossRef
120.
Ferreira RC, Pan-Hammarström Q, Graham RR, Gateva V, Fontán G, Lee AT, Ortmann W, Urcelay E, Fernández-Arquero M, Núñez C et al (2010) Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat Genet 42(9):777–780PubMedCrossRef
121.
Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y, Komatsu N, Umeda N, Hosokawa T, Ueda K et al (2008) Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 134(5):1396–1405PubMedCrossRef
122.
International Multiple Sclerosis Genetics Consortium (2009) The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 10(1):11–14CrossRef
123.
Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39(7):857–864PubMedPubMedCentralCrossRef
124.
Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Casalunovo T, Taback SP, Frackelton EC et al (2007) A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448(7153):591–594PubMedCrossRef
125.
Zoledziewska M, Costa G, Pitzalis M, Cocco E, Melis C, Moi L, Zavattari P, Murru R, Lampis R, Morelli L et al (2009) Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun 10(1):15–17PubMedCrossRef
126.
Wu X, Zhu X, Wang X, Ma J, Zhu S, Li J, Liu Y (2009) Intron polymorphism in the KIAA0350 gene is reproducibly associated with susceptibility to type 1 diabetes (T1D) in the Han Chinese population. Clin Endocrinol (Oxf) 71(1):46–49PubMedCrossRef
127.
Reddy MV, Wang H, Liu S, Bode B, Reed JC, Steed RD, Anderson SW, Steed L, Hopkins D, She JX (2011) Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian population. Genes Immun 12(3):208–212PubMedPubMedCentralCrossRef
128.
Martínez A, Perdigones N, Cénit MC, Espino L, Varadé J, Lamas JR, Santiago JL, Fernández-Arquero M, de la Calle H, Arroyo R et al (2010) Chromosomal region 16p13: further evidence of increased predisposition to immune diseases. Ann Rheum Dis 69(1):309–311PubMedCrossRef
129.
Español T, Catala M, Hernandez M, Caragol I, Bertran JM (1996) Development of a common variable immunodeficiency in IgA-deficient patients. Clin Immunol Immunopathol 80(3 Pt 1):333–335PubMedCrossRef
130.
Aghamohammadi A, Mohammadi J, Parvaneh N, Rezaei N, Moin M, Espanol T, Hammarstrom L (2008) Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol 147(2):87–92PubMedCrossRef
131.
Chapel H, Cunningham-Rundles C (2009) Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 145(6):709–727PubMedPubMedCentralCrossRef
132.
Ho HE, Cunningham-Rundles C (2020) Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol 11:149PubMedPubMedCentralCrossRef
133.
Warnatz K, Denz A, Dräger R, Braun M, Groth C, Wolff-Vorbeck G, Eibel H, Schlesier M, Peter HH (2002) Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99(5):1544–1551PubMedCrossRef
134.
135.
Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, Hammarström L, Nonoyama S, Quinti I et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4(1):38–59PubMedCrossRef
136.
Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA et al (2005) Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37(8):820–828PubMedCrossRef
137.
Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS (2005) TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37(8):829–834PubMedCrossRef
138.
Zhang L, Radigan L, Salzer U, Behrens TW, Grimbacher B, Diaz G, Bussel J, Cunningham-Rundles C (2007) Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol 120(5):1178–1185PubMedPubMedCentralCrossRef
139.
Jacobs HM, Thouvenel CD, Leach S, Arkatkar T, Metzler G, Scharping NE, Kolhatkar NS, Rawlings DJ, Jackson SW (2016) Cutting edge: BAFF promotes autoantibody production via TACI-dependent activation of transitional B cells. J Immunol 196(9):3525–3531PubMedCrossRef
140.
Scott O, Roifman CM (2019) NF-κB pathway and the Goldilocks principle: lessons from human disorders of immunity and inflammation. J Allergy Clin Immunol 143(5):1688–1701PubMedCrossRef
141.
Tuijnenburg P, Lango Allen H, Burns SO, Greene D, Jansen MH, Staples E, Stephens J, Carss KJ, Biasci D, Baxendale H et al (2018) Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. J Allergy Clin Immunol 142(4):1285–1296PubMedPubMedCentralCrossRef
142.
Lougaris V, Patrizi O, Baronio M, Tabellini G, Tampella G, Damiati E, Frede N, van der Meer JWM, Fliegauf M, Grimbacher B et al (2017) NFKB1 regulates human NK cell maturation and effector functions. Clin Immunol 175:99–108PubMedCrossRef
143.
Klemann C, Camacho-Ordonez N, Yang L, Eskandarian Z, Rojas-Restrepo JL, Frede N, Bulashevska A, Heeg M, Al-Ddafari MS, Premm J et al (2019) Clinical and immunological phenotype of patients with primary immunodeficiency due to damaging mutations in NFKB2. Front Immunol 10:297PubMedPubMedCentralCrossRef
144.
Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thon V, Abedi MR, Hammarstrom L (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112(2):277–286PubMedCrossRef
145.
Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F et al (2007) Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 27(3):308–316PubMedCrossRef
146.
Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, Detkova D, Bos PR et al (2008) The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111(1):77–85PubMedCrossRef
147.
Farmer JR, Ong MS, Barmettler S, Yonker LM, Fuleihan R, Sullivan KE, Cunningham-Rundles C, Walter JE (2017) Common variable immunodeficiency non-infectious disease endotypes redefined using unbiased network clustering in large electronic datasets. Front Immunol 8:1740PubMedCrossRef
148.
Wang J, Cunningham-Rundles C (2005) Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 25(1):57–62PubMedCrossRef
149.
150.
Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106(12):R75-81PubMedPubMedCentralCrossRef
151.
Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20–21PubMedCrossRef
152.
Kobayashi I, Shiari R, Yamada M, Kawamura N, Okano M, Yara A, Iguchi A, Ishikawa N, Ariga T, Sakiyama Y et al (2001) Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). J Med Genet 38(12):874–876PubMedPubMedCentralCrossRef
153.
Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW (2007) CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 119(2):482–487PubMedCrossRef
154.
Aaltonen J, Björses P, Perheentupa J, Horelli-Kuitunen N, Palotie A, Peltonen L, Lee YS, Francis F, Henning S, Thiel C, Leharach H (1997) An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 17(4):399–403CrossRef
155.
Constantine GM, Lionakis MS (2019) Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol Rev 287(1):103–120PubMedPubMedCentralCrossRef
156.
157.
Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB, Break TJ, Gu W, Hunsberger S et al (2016) Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1(13):e88782PubMedPubMedCentralCrossRef
158.
Capalbo D, De Martino L, Giardino G, Di Mase R, Di Donato I, Parenti G, Vajro P, Pignata C, Salerno M (2012) Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights into genotype-phenotype correlation. Int J Endocrinol 2012:353250PubMedPubMedCentralCrossRef
159.
García-Lozano JR, Torres-Agrela B, Montes-Cano MA, Ortiz-Fernández L, Conde-Jaldón M, Teruel M, García A, Núñez-Roldán A, Martín J, González-Escribano MF (2013) Association of the AIRE gene with susceptibility to rheumatoid arthritis in a European population: a case control study. Arthritis Res Ther 15(1):R11PubMedPubMedCentralCrossRef
160.
Bérczi B, Gerencsér G, Farkas N, Hegyi P, Veres G, Bajor J, Czopf L, Alizadeh H, Rakonczay Z, Vigh É et al (2017) Association between AIRE gene polymorphism and rheumatoid arthritis: a systematic review and meta-analysis of case-control studies. Sci Rep 7(1):14096PubMedPubMedCentralCrossRef
161.
Colobran R, Giménez-Barcons M, Marín-Sánchez A, Porta-Pardo E, Pujol-Borrell R (2016) AIRE genetic variants and predisposition to polygenic autoimmune disease: the case of Graves’ disease and a systematic literature review. Hum Immunol 77(8):643–651PubMedCrossRef
162.
Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81(6):935–946PubMedCrossRef
163.
Caminha I, Fleisher TA, Hornung RL, Dale JK, Niemela JE, Price S, Davis J, Perkins K, Dowdell KC, Brown MR et al (2010) Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 125(4):946-949.e946PubMedPubMedCentralCrossRef
164.
Bowen RA, Dowdell KC, Dale JK, Drake SK, Fleisher TA, Hortin GL, Remaley AT, Nexo E, Rao VK (2012) Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem 45(6):490–492PubMedPubMedCentralCrossRef
165.
Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT et al (2010) Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 116(14):e35-40PubMedPubMedCentralCrossRef
166.
Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J et al (2001) The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98(1):194–200PubMedCrossRef
167.
Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, Lanzarotti N, Stolzenberg MC, Bader-Meunier B, Aladjidi N et al (2011) A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 118(18):4798–4807PubMedCrossRef
168.
Kanegane H, Vilela MM, Wang Y, Futatani T, Matsukura H, Miyawaki T (2003) Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. Pediatr Nephrol 18(5):454–456PubMedCrossRef
169.
Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J et al (2014) Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46(8):812–814PubMedPubMedCentralCrossRef
170.
Haapaniemi EM, Kaustio M, Rajala HL, van Adrichem AJ, Kainulainen L, Glumoff V, Doffinger R, Kuusanmäki H, Heiskanen-Kosma T, Trotta L et al (2015) Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125(4):639–648PubMedPubMedCentralCrossRef
171.
Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N et al (2015) Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125(4):591–599PubMedPubMedCentralCrossRef
172.
Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Mory A et al (2012) Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 90(6):986–1001PubMedPubMedCentralCrossRef
173.
Burns SO, Zenner HL, Plagnol V, Curtis J, Mok K, Eisenhut M, Kumararatne D, Doffinger R, Thrasher AJ, Nejentsev S (2012) LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol 130(6):1428–1432PubMedPubMedCentralCrossRef
174.
Habibi S, Zaki-Dizaji M, Rafiemanesh H, Lo B, Jamee M, Gámez-Díaz L, Salami F, Kamali AN, Mohammadi H, Abolhassani H et al (2019) Clinical, immunologic, and molecular spectrum of patients with LPS-responsive beige-like anchor protein deficiency: a systematic review. J Allergy Clin Immunol Pract 7(7):2379-2386.e2375PubMedCrossRef
175.
Charbonnier LM, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, Massaad MJ, Garcia-Lloret M, Hanna-Wakim R, Dbaibo G et al (2015) Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol 135(1):217–227PubMedCrossRef
176.
Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, Raddaoui E, Almomen AK, Al-Muhsen S, Geha RS et al (2012) LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 130(2):481-488.e482PubMedPubMedCentralCrossRef
177.
Schreiner F, Plamper M, Dueker G, Schoenberger S, Gámez-Díaz L, Grimbacher B, Hilger AC, Gohlke B, Reutter H, Woelfle J (2016) Infancy-onset T1DM, Short stature, and severe immunodysregulation in two siblings with a homozygous LRBA mutation. J Clin Endocrinol Metab 101(3):898–904PubMedCrossRef
178.
Al-Mayouf SM, Naji H, Alismail K, Alazami AM, Sheikh F, Conca W, Al-Mousa H (2017) Evolving spectrum of LRBA deficiency-associated chronic arthritis: is there a causative role in juvenile idiopathic arthritis? Clin Exp Rheumatol 35(2):327–329PubMed
179.
Serwas NK, Kansu A, Santos-Valente E, Kuloğlu Z, Demir A, Yaman A, Gamez Diaz LY, Artan R, Sayar E, Ensari A et al (2015) Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis 21(1):40–47PubMedCrossRef
180.
181.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623–1627PubMedPubMedCentralCrossRef
182.
Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, Laerdahl JK, Stade B, Forster M, Schreiber S et al (2015) Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut 64(12):1889–1897PubMedCrossRef
183.
Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M et al (2018) Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol 142(6):1932–1946PubMedPubMedCentralCrossRef
184.
Bridges RA, Berendes H, Good RA (1959) A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child 97(4):387–408PubMedCrossRef
185.
Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DA, Soule BP et al (2010) Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 363(27):2600–2610PubMedPubMedCentralCrossRef
186.
Martel C, Mollin M, Beaumel S, Brion JP, Coutton C, Satre V, Vieville G, Callanan M, Lefebvre C, Salmon A et al (2012) Clinical, functional and genetic analysis of twenty-four patients with chronic granulomatous disease - identification of eight novel mutations in CYBB and NCF2 genes. J Clin Immunol 32(5):942–958PubMedCrossRef
187.
Ameratunga R, Woon ST, Vyas J, Roberts S (2010) Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin Pediatr (Phila) 49(12):1143–1146PubMedCrossRef
188.
Dotis J, Pana ZD, Roilides E (2013) Non-Aspergillus fungal infections in chronic granulomatous disease. Mycoses 56(4):449–462PubMedCrossRef
189.
Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS (2004) T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol 5(8):818–827PubMedCrossRef
190.
Romani L, Fallarino F, De Luca A, Montagnoli C, D’Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Grohmann U et al (2008) Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451(7175):211–215PubMedCrossRef
191.
Kraaij MD, Savage ND, van der Kooij SW, Koekkoek K, Wang J, van den Berg JM, Ottenhoff TH, Kuijpers TW, Holmdahl R, van Kooten C et al (2010) Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc Natl Acad Sci U S A 107(41):17686–17691PubMedPubMedCentralCrossRef
192.
van de Geer A, Cuadrado E, Slot MC, van Bruggen R, Amsen D, Kuijpers TW (2019) Regulatory T cell features in chronic granulomatous disease. Clin Exp Immunol 197(2):222–229PubMedPubMedCentralCrossRef
193.
De Ravin SS, Naumann N, Robinson MR, Barron KS, Kleiner DE, Ulrick J, Friend J, Anderson VL, Darnell D, Kang EM et al (2006) Sarcoidosis in chronic granulomatous disease. Pediatrics 117(3):e590-595PubMedCrossRef
194.
Lee BW, Yap HK (1994) Polyarthritis resembling juvenile rheumatoid arthritis in a girl with chronic granulomatous disease. Arthritis Rheum 37(5):773–776PubMedCrossRef
195.
De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, Balow JE, Barron KS, Turner ML, Gallin JI et al (2008) Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 122(6):1097–1103PubMedPubMedCentralCrossRef
196.
Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J, Kreuzburg S, Yockey L, Hunsberger S, Foruraghi L et al (2018) X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol 141(1):365–371PubMedCrossRef
197.
Battersby AC, Cale AM, Goldblatt D, Gennery AR (2013) Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. J Clin Immunol 33(8):1276–1284PubMedCrossRef
198.
Leffler J, Bengtsson AA, Blom AM (2014) The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 73(9):1601–1606PubMedCrossRef
199.
Wen L, Atkinson JP, Giclas PC (2004) Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 113(4):585–593PubMedCrossRef
200.
Aggarwal R, Sestak AL, D’Souza A, Dillon SP, Namjou B, Scofield RH (2010) Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 19(1):52–57PubMedCrossRef
201.
West CD, McAdams AJ (1999) The alternative pathway C3 convertase and glomerular deposits. Pediatr Nephrol 13(5):448–453PubMedCrossRef
202.
Levy Y, George J, Yona E, Shoenfeld Y (1998) Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation: An autoimmune phenomenon. Immunol Res 18(1):55–60PubMedCrossRef
203.
Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN, Jones JV, Katzenstein PL, McFadden ER, McMillen JJ, Pick MA et al (1995) Hypocomplementemic urticarial vasculitis syndrome: Clinical and serologic findings in 18 patients. Medicine (Baltimore) 74(1):24–41PubMedCrossRef
204.
Gilliam BE, Wolff AE, Moore TL (2007) Partial C4 deficiency in juvenile idiopathic arthritis patients. J Clin Rheumatol 13(5):256–260PubMedCrossRef
205.
Stengaard-Pedersen K, Thiel S, Gadjeva M, Møller-Kristensen M, Sørensen R, Jensen LT, Sjøholm AG, Fugger L, Jensenius JC (2003) Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 349(6):554–560PubMedCrossRef
206.
García-Laorden MI, Hernández-Brito E, Muñoz-Almagro C, Pavlovic-Nesic S, Rúa-Figueroa I, Briones ML, Rajas O, Borderías L, Payeras A, Lorente L et al (2020) Should MASP-2 deficiency be considered a primary immunodeficiency? Relevance of the Lectin Pathway. J Clin Immunol 40(1):203–210PubMedCrossRef
207.
Heimall J (2019) Now is the time to use molecular gene testing for the diagnosis of primary immune deficiencies. J Allergy Clin Immunol Pract 7(3):833–838PubMedCrossRef
208.
Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C (2012) Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119(7):1650–1657PubMedPubMedCentralCrossRef
209.
Ozsoylu F (2004) Megadose methylprednisolone for the treatment of patients with Evans syndrome. Pediatr Hematol Oncol 21(8):739–740PubMedCrossRef
210.
211.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829–3866PubMedPubMedCentralCrossRef
212.
Walter JE, Farmer JR, Foldvari Z, Torgerson TR, Cooper MA (2016) Mechanism-based strategies for the management of autoimmunity and immune dysregulation in primary immunodeficiencies. J Allergy Clin Immunol Pract 4(6):1089–1100PubMedPubMedCentralCrossRef
213.
Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, Dogruel D, Karaca NE, Cogurlu MT, Bilir OA et al (2019) Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract 7(8):2790-2800.e2715PubMedPubMedCentralCrossRef
Metadaten
Titel
Autoimmunity in Primary Immunodeficiencies (PID)
verfasst von
Grace T. Padron
Vivian P. Hernandez-Trujillo
Publikationsdatum
01.06.2022
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 1/2023
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-022-08942-0

Weitere Artikel der Ausgabe 1/2023

Clinical Reviews in Allergy & Immunology 1/2023 Zur Ausgabe

Review

Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity

ReviewPaper

Microbial Dysbiosis Tunes the Immune Response Towards Allergic Disease Outcomes

ReviewPaper

The Treatment of Primary Immune Deficiencies: Lessons Learned and Future Opportunities

ReviewPaper

The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity

ReviewPaper

T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise